An international study has shown that Hodgkin lymphoma recurrence and drug response can be predicted using the levels of circulating tumor DNA (ctDNA) in a patient’s blood. The Stanford Medicine-led research, reported in Nature, examined hundreds of samples from patients with classic Hodgkin lymphoma (cHL) and suggests that profiling using…

Late last week, big pharma company Roche announced FDA approval of its bi-specific antibody Lunsumio for the treatment of people with a relapsed or refractory form of non-Hodgkin lymphoma, follicular lymphoma (FL). The regulatory nod comes under an accelerated approval based on a Phase II pivotal study that showed an…

People with early-stage Hodgkin lymphoma are now more likely to die from cardiovascular disease than their cancer, reveal results from a long-term cohort study led by Southern Medical University in Guangzhou, China. Hodgkin lymphoma accounts for around 10% of all lymphomas and treatment advances mean that the 10-year survival rate…

A team of researchers at the Swiss Federal Institute of Technology Lausanne (EPFL) have identified protein cathepsin S. (CTSS) as a mechanism used by Non-Hodgkin lymphoma (NHL) to evade the immune system.  This discovery provides a future target for clinical NHL treatment. A scientific team led by Elisa Oricchio, Ph.D.,…

A study from researchers at MD Anderson Cancer Center and Weill Cornell Medical School, published today in Cancer Discovery has demonstrated a new approach to treating two of the most common subtypes of lymphoma via manipulation of molecular programs controlled by the cAMP-response element binding protein (CREBBP). CREBBP mutations are…

Caris Life Sciences said today it has identified a new mechanism of action for an aptamer with potential to treat non-Hodgkin lymphoma (NHL), using its proprietary ADAPT Biotargeting System. At the 59th American Society of Hematology (ASH) Annual Meeting & Exposition in Atlanta, Caris presented results from a study, Aptamer C10.36…

A targeted therapy has significantly reduced relapse rates among children with high-risk Hodgkin’s lymphoma (HL) in a multicenter clinical trial. Patients who received the targeted antibody-drug conjugate (ADC) brentuximab vedotin (BV), with the standard chemotherapy regimen, were 10% less likely to relapse. The findings were published in the New England…

Molecular biology company Caris Life Sciences has published new data in Cell Chemical Biology that could offer a new pathway to the treatment of Non-Hodgkin’s Lymphoma. In the paper “Translocation of a cell surface spliceosomal complex induces alternative splicing events and lymphoma cell necrosis,” researchers identified a molecular spliceosomal complex…

Gut microorganisms influence non-Hodgkin lymphoma patient outcomes to chimeric antigen receptor T-cell (CAR T) therapy, according to a recent multinational research collaboration. A key finding of this study was that patients who had higher levels of the bacterium Bifidobacterium longum had an improved overall survival rate after CAR T. The team…

AbbVie and Genmab have announced topline results from the first cohort of the EPCORE phase 1/2 clinical trial of epcoritamab (DuoBody-CD3xCD20), an investigational subcutaneous bispecific antibody they are co-developing. The study cohort includes 157 patients with relapsed/refractory large B-cell lymphoma (LBCL) who received at least two prior lines of systemic…

Data from three separate clinical studies, released at the American Society Hematology (ASH) conference in December by researchers from the MD Anderson Cancer Center, showed enhanced response in patients with high-risk lymphoma when treated with axicabtagene ciloleucel (axi-cel) chimeric antigen receptor (CAR) T-cell therapy. Axi-cel is an autologous anti-CD19 CAR…

Scientists based at Icahn School of Medicine at Mount Sinai have discovered a new class of drugs that they think has potential to treat a subtype of non-Hodgkin’s lymphoma—mantle cell lymphoma—that is normally fatal. The drug candidates are small molecules that inhibit the action of the SOX11 oncogene and in…

Cytokine-activated natural killer (NK) cells, combined with an investigational bispecific antibody targeting CD16a and CD30 (AFM13), showed potent anti-tumor activity against CD30+ lymphoma cells, according to a new study from researchers at The University of Texas MD Anderson Cancer Center. “This preclinical work provided proof of principle for NK cells…

Scientists at Stanford University School of Medicine have just described in a new study how sequencing minute bits of DNA circulating in the blood of lymphoma patients can accurately identify the cancer subtype and pinpoint mutations that might cause drug resistance. The findings from this new study were published recently…

Patients with chronic lymphoblastic leukemia (CLL) and non-Hodgkin lymphoma (NHL) were less likely to experience severe infection if they received frequent testing for immunoglobulin G (IgG)—proteins in the immune system that are at low levels in patients with these blood cancers. The new research, published today in the journal Blood…